AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34585083 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 1567
Study 34585083 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 1567
Study 34585271 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ICU admission
Number of subjects: 530
Study 34585271 — intervention group
Group type: COMPARATOR
Intervention: Delayed ICU admission
Number of subjects: 530
Study 34585329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 79
Study 34585329 — intervention group
Group type: COMPARATOR
Intervention: Reference group (Control)
Number of subjects: 79
Study 34585343 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive central pressure estimation before endovascular repair
Number of subjects: 20
Study 34585343 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive central pressure estimation after endovascular repair
Number of subjects: 20
Study 34585621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 296
Study 34585621 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 296
Study 34585638 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy for endometrioma
Number of subjects: 0
Study 34585638 — intervention group
Group type: COMPARATOR
Intervention: Other types of infertility (unexplained, tubal factor, male factor)
Number of subjects: 0
Study 34585740 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with antimalarial drugs
Number of subjects: 13
Study 34585950 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 301
Study 34585950 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 301
Study 34586075 — intervention group
Group type: EXPERIMENTAL
Intervention: POD Adventures intervention delivered over 4 weeks
Number of subjects: 70
Study 34586075 — intervention group
Group type: COMPARATOR
Intervention: Usual care comprising information about local mental health services and national helplines
Number of subjects: 70
Study 34586417 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous kidney replacement therapy (CKRT)
Number of subjects: 340
Study 34586417 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 340
Study 34586417 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 340
Study 34586417 — intervention group
Group type: COMPARATOR
Intervention: Children with three comorbidities
Number of subjects: 340
Study 34586417 — intervention group
Group type: COMPARATOR
Intervention: Children with no comorbidities
Number of subjects: 340
Study 34586461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic traction suture
Number of subjects: 43
Study 34586461 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group not explicitly mentioned)
Number of subjects: 43
Study 34586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (100-215 mg/m, orally once or twice-daily)
Number of subjects: 36
Study 34586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib in combination with dasatinib
Number of subjects: 36
Study 34586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib in overweight/obese patients
Number of subjects: 36
Study 34586748 — intervention group
Group type: EXPERIMENTAL
Intervention: molar NT-proBNP/BNP ratio
Number of subjects: 782
Study 34586748 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP or BNP alone
Number of subjects: 782
Study 34586924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gene expression classifier
Number of subjects: 190
Study 34586924 — intervention group
Group type: COMPARATOR
Intervention: Chemo-radiation and image guided adaptive brachytherapy
Number of subjects: 190
Study 34587198 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention including remote monitoring through ABPM, ECG, spirometry, sleep oximetry, and a smartphone app for home monitoring of BP, HR, SpO2, body temperature, body weight, waist circumference, blood glucose, and lipids.
Number of subjects: 13613
Study 34587198 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention during lockdown period.
Number of subjects: 13613
Study 34587198 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-lockdown period monitoring.
Number of subjects: 13613
Study 34587245 — intervention group
Group type: EXPERIMENTAL
Intervention: High nutritional risk (NutriSTEP score ≥21)
Number of subjects: 896
Study 34587245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-SD increase in NutriSTEP total score
Number of subjects: 896
Study 34587245 — intervention group
Group type: EXPERIMENTAL
Intervention: NutriSTEP total score
Number of subjects: 896
Study 34587246 — intervention group
Group type: EXPERIMENTAL
Intervention: FlowCT analysis of T-cell compartment in bone marrow (BM) and peripheral blood (PB)
Number of subjects: 250
Study 34587246 — intervention group
Group type: EXPERIMENTAL
Intervention: FlowCT analysis of T-cell compartment in BM of patients with active MM after treatment intensification
Number of subjects: 250
Study 34587246 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 250
Study 34587796 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-MERGE MRI
Number of subjects: 227
Study 34587796 — intervention group
Group type: COMPARATOR
Intervention: 2D-MC MRI
Number of subjects: 227
Study 34587913 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for AIS in patients with AF
Number of subjects: 1755
Study 34587913 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) for AIS in patients without AF
Number of subjects: 1755
Study 34588193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab (8 mg·kg)
Number of subjects: 29
Study 34588255 — intervention group
Group type: EXPERIMENTAL
Intervention: First pulmonary embolism with cardiac involvement
Number of subjects: 417
Study 34588255 — intervention group
Group type: COMPARATOR
Intervention: First pulmonary embolism without cardiac involvement (non-severe)
Number of subjects: 417
Study 34588255 — intervention group
Group type: EXPERIMENTAL
Intervention: Provoked PE with cardiac involvement
Number of subjects: 417
Study 34588255 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of first PE
Number of subjects: 417
Study 34588264 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI) assessment of decision-making capacity (DMC)
Number of subjects: 0
Study 34588264 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment of DMC by a geriatrician based on neuropsychological tests
Number of subjects: 0
Study 34588274 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function assessment
Number of subjects: 114
Study 34588274 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 114
Study 34588274 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe fatigue assessment
Number of subjects: 114
Study 34588274 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) independence
Number of subjects: 114
Study 34588274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment assessment
Number of subjects: 114
Study 34588274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health assessment (depression, anxiety, PTSD)
Number of subjects: 114
Study 34588274 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life
Number of subjects: 114
Study 34588763 — intervention group
Group type: EXPERIMENTAL
Intervention: wDDART (web-based Democritus Digital Acuity Reading Test)
Number of subjects: 100
Study 34588763 — intervention group
Group type: COMPARATOR
Intervention: DDART (conventional Windows-based reading test)
Number of subjects: 100
Study 34588763 — intervention group
Group type: EXPERIMENTAL
Intervention: wDDART
Number of subjects: 100
Study 34588990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction
Number of subjects: 0
Study 34588990 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34589194 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI) with Nuwiq
Number of subjects: 120
Study 34589194 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 120
Study 34589194 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI with emicizumab prophylaxis
Number of subjects: 120
Study 34589194 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study 34589419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobaplatin plus docetaxel
Number of subjects: 458
Study 34589419 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus docetaxel
Number of subjects: 458
Study 34589902 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram/memantine (ESC/MEM)
Number of subjects: 90
Study 34589902 — intervention group
Group type: COMPARATOR
Intervention: escitalopram/placebo (ESC/PBO)
Number of subjects: 90
Study 34589918 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Prognostic Score (SPS) based on clinical and biological variables including TNM stage, performance status, liver metastases, and neutrophil-to-lymphocyte ratio.
Number of subjects: 401
Study 34589918 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 401
Study 34589965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegargiminase (ADI-PEG 20) plus Pemetrexed and Cisplatin (ADIPemCis)
Number of subjects: 32
Study 34589965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegargiminase (ADI-PEG 20)
Number of subjects: 32
Study 34589978 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based smoking cessation counseling intervention
Number of subjects: 337
Study 34589978 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information pamphlet)
Number of subjects: 337
Study 34589984 — intervention group
Group type: EXPERIMENTAL
Intervention: Rociletinib 500 mg twice daily
Number of subjects: 149
Study 34589984 — intervention group
Group type: EXPERIMENTAL
Intervention: Rociletinib 625 mg twice daily
Number of subjects: 149
Study 34589984 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 149
Study 34589984 — intervention group
Group type: EXPERIMENTAL
Intervention: Rociletinib (500 mg and 625 mg twice daily) in T790M-positive patients
Number of subjects: 149
Study 34590023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus Erlotinib (RAM + ERL)
Number of subjects: 211
Study 34590023 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Erlotinib (PL + ERL)
Number of subjects: 211
Study 34590034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg, flat dose on day 1, every 3 weeks for 2 years) plus Amrubicin (40 mg/m2)
Number of subjects: 25
Study 34590034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Amrubicin
Number of subjects: 25
Study 34590048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg, 10 mg/kg, or 200 mg every 3 weeks or 10 mg/kg every 2 weeks)
Number of subjects: 3170
Study 34590048 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 3170
Study 34590048 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 3170
Study 34590052 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d
Number of subjects: 32
Study 34590052 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 34590052 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d (part A)
Number of subjects: 32
Study 34590052 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk plus afatinib 40 mg/d (part B)
Number of subjects: 32
Study 34590303 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier corticosteroid and tocilizumab use
Number of subjects: 0
Study 34590303 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34590307 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood or PRP injection
Number of subjects: 2337
Study 34590610 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Secretase Inhibitor AL101
Number of subjects: 2
Study 34591023 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch-enabled remote monitoring with SmokeBeat program for 12 weeks
Number of subjects: 39
Study 34591023 — intervention group
Group type: COMPARATOR
Intervention: No remote monitoring for 12 weeks
Number of subjects: 39
Study 34591023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-to-wear program for 4 weeks
Number of subjects: 39
Study 34591023 — intervention group
Group type: COMPARATOR
Intervention: Pay-to-quit program for 4 weeks
Number of subjects: 39
Study 34591023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-to-quit program with higher incentives for 3 weeks
Number of subjects: 39
Study 34591024 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning algorithms (CNN)
Number of subjects: 18813
Study 34591024 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning algorithms (RNN)
Number of subjects: 18813
Study 34591024 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression algorithm
Number of subjects: 18813
Study 34591024 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP-OP (weighted average of deep-learning models)
Number of subjects: 18813
Study 34591030 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Companion smartphone application
Number of subjects: 0
Study 34591030 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian network (BN) algorithm
Number of subjects: 0
Study 34591807 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative EEG with lower spectral edge frequency (SEF)
Number of subjects: 237
Study 34591807 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative EEG with lower γ-band power
Number of subjects: 237
Study 34591807 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinduction absolute α-band power
Number of subjects: 237
Study 34591807 — intervention group
Group type: EXPERIMENTAL
Intervention: SEF ratio from preoperative to postinduction state
Number of subjects: 237
Study 34591807 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative SEF, preoperative γ-band power, and SEF ratio
Number of subjects: 237
Study 34591989 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients with CLL
Number of subjects: 0
Study 34591989 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with CLL
Number of subjects: 0
Study 34592057 — intervention group
Group type: EXPERIMENTAL
Intervention: BACE1 inhibitors
Number of subjects: 3536
Study 34592057 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (NB, kNN, SVM, RF, XGB)
Number of subjects: 3536
Study 34592319 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISm (Preserved Ratio Impaired Spirometry)
Number of subjects: 1775
Study 34592319 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISm
Number of subjects: 1775
Study 34592755 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRαβ/CD19-depleted haploidentical HSCT from an HLA-partially matched relative
Number of subjects: 70
Study 34592798 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Once Monthly
Number of subjects: 0
Study 34592798 — intervention group
Group type: COMPARATOR
Intervention: Daily Oral Atypical Antipsychotic Treatment
Number of subjects: 0
Study 34592998 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for any cause
Number of subjects: 1002
Study 34592998 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory-related hospitalization
Number of subjects: 1002
Study 34592998 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization with ventilatory support
Number of subjects: 1002
Study 34592998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality during hospitalization or within 90 days of discharge
Number of subjects: 1002
Study 34592998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality associated with respiratory hospitalization or hospitalization with ventilatory support
Number of subjects: 1002
Study 34593001 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS2 ≥ 5
Number of subjects: 323
Study 34593001 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS2 ≥ 7
Number of subjects: 323
Study 34593001 — intervention group
Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tools ≥ 2
Number of subjects: 323
Study 34593001 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS2
Number of subjects: 323
Study 34593001 — intervention group
Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tools
Number of subjects: 323
Study 34593001 — intervention group
Group type: EXPERIMENTAL
Intervention: RETTS ≥ orange
Number of subjects: 323
Study 34593173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL 4.0 GCS)
Number of subjects: 329
Study 34593270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional (1/5th dose-volume) RTS,S/AS01
Number of subjects: 49
Study 34593491 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scan and PSA blood test
Number of subjects: 0
Study 34593491 — intervention group
Group type: COMPARATOR
Intervention: Standard of care tests for prostate cancer assessment (including multiparametric MRI)
Number of subjects: 0
Study 34593490 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR-DBS (mesencephalic locomotor region deep brain stimulation) during locomotion training
Number of subjects: 1
Study 34593497 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional diagnostic tests including infection markers, POC urine flow cytometry, POC analysis of sputum, POC and specialist ultrasound, and ULDCT
Number of subjects: 1000
Study 34593530 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly trained classifiers
Number of subjects: 0
Study 34593600 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for acute large vessel occlusion (LVO)
Number of subjects: 1557
Study 34593959 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Resolution Melting (HRM) assays to genotype Pfs47 SNPs 707 and 725
Number of subjects: 4971
Study 34593959 — intervention group
Group type: COMPARATOR
Intervention: Pfs47 sequences from Africa, Asia, and the New World
Number of subjects: 4971
Study 34593959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfs47 sequences from Papua New Guinea
Number of subjects: 4971
Study 34594036 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (first dose)
Number of subjects: 53
Study 34594036 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (second dose)
Number of subjects: 53
Study 34594036 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (third dose)
Number of subjects: 53
Study 34594036 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (participants without cancer)
Number of subjects: 53
Study 34595223 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial transplantation of autologous cardiac micrografts during coronary artery bypass surgery
Number of subjects: 0
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ANA testing in patients with gastroparesis
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ANA in idiopathic gastroparesis
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ANA in T1DM gastroparesis
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ANA in T2DM gastroparesis
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ANA in postfundoplication gastroparesis
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA titer levels in idiopathic gastroparesis
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ANA positivity with gender and ethnicity
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ANA positivity with comorbidities
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of ANA positivity on GCSI
Number of subjects: 893
Study 34595805 — intervention group
Group type: EXPERIMENTAL
Intervention: Relation of ANA positivity to gastric emptying
Number of subjects: 893
Study 34595830 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum dietary restrictions
Number of subjects: 682
Study 34595830 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 682
Study 34596039 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable negative external pressure (vNEP) therapy
Number of subjects: 28
Study 34596097 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling training (3 sessions/week)
Number of subjects: 1
Study 34596097 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling training (2-4 sessions/week)
Number of subjects: 1
Study 34596097 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling training
Number of subjects: 1
Study 34596223 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Number of subjects: 45542
Study 34596223 — intervention group
Group type: COMPARATOR
Intervention: Non-Remdesivir (non-RDV)
Number of subjects: 45542
Study 34596223 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV) for NSO
Number of subjects: 45542
Study 34596223 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV) for LFO
Number of subjects: 45542
Study 34596223 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV) for IMV/ECMO
Number of subjects: 45542
Study 34596223 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV) for HFO/NIV
Number of subjects: 45542
Study 34596445 — intervention group
Group type: EXPERIMENTAL
Intervention: Surprise Question responses
Number of subjects: 250
Study 34596770 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Scan digital occlusal analysis system
Number of subjects: 40
Study 34596770 — intervention group
Group type: COMPARATOR
Intervention: CEREC Omnicam system
Number of subjects: 40